TY - JOUR
T1 - Impact of early rasburicase on incidence of clinical tumor lysis syndrome in lymphoma
AU - Personett, Heather A.
AU - Barreto, Erin F.
AU - McCullough, Kristen B.
AU - Dierkhising, Ross
AU - Leung, Nelson
AU - Habermann, Thomas M.
N1 - Funding Information:
This work was funded in part by a small grant from the Mayo Midwest Pharmacy Research Committee.
Publisher Copyright:
© 2019, © 2019 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2019/7/29
Y1 - 2019/7/29
N2 - Early administration of rasburicase to enhance uric acid (UA) elimination has been adopted without robust evidence in support of its impact on clinical outcomes in tumor lysis syndrome (TLS), specifically, the prevention of acute kidney injury (AKI). This was a retrospective cohort study of adult lymphoma patients at intermediate or high risk for TLS. Excluded patients had AKI or were on dialysis at hospital admission. The incidence of new AKI in the setting of TLS was described along with predictors of its development, including early rasburicase use. In 383 included patients, the incidence of new-onset AKI during hospitalization was 6%. Predictors included age, history of renal or cardiovascular disease, and UA >8 mg/dL. Rasburicase use did not significantly impact the risk of developing AKI (HR 2.3; p =.11). The UA level at the time of administration did not modify the effect of rasburicase on prevention of AKI (p =.36 for the interaction term).
AB - Early administration of rasburicase to enhance uric acid (UA) elimination has been adopted without robust evidence in support of its impact on clinical outcomes in tumor lysis syndrome (TLS), specifically, the prevention of acute kidney injury (AKI). This was a retrospective cohort study of adult lymphoma patients at intermediate or high risk for TLS. Excluded patients had AKI or were on dialysis at hospital admission. The incidence of new AKI in the setting of TLS was described along with predictors of its development, including early rasburicase use. In 383 included patients, the incidence of new-onset AKI during hospitalization was 6%. Predictors included age, history of renal or cardiovascular disease, and UA >8 mg/dL. Rasburicase use did not significantly impact the risk of developing AKI (HR 2.3; p =.11). The UA level at the time of administration did not modify the effect of rasburicase on prevention of AKI (p =.36 for the interaction term).
KW - Lymphoma and Hodgkin disease
KW - acute kidney injury
KW - lymphoid leukemia
KW - pharmacotherapeutics
KW - rasburicase
KW - tumor lysis syndrome
UR - http://www.scopus.com/inward/record.url?scp=85067866930&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85067866930&partnerID=8YFLogxK
U2 - 10.1080/10428194.2019.1574000
DO - 10.1080/10428194.2019.1574000
M3 - Article
C2 - 31223041
AN - SCOPUS:85067866930
SN - 1042-8194
VL - 60
SP - 2271
EP - 2277
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 9
ER -